HENRY MASUR, M.D.; H. CLIFFORD LANE, M.D.; ALAN PALESTINE, M.D.; PHILLIP D. SMITH, M.D.; JODY MANISCHEWITZ, M.D.; GARTH STEVENS, M.D.; LESLIE FUJIKAWA, M.D.; ABE M. MACHER, M.D.; ROBERT NUSSENBLATT, M.D.; BARBARA BAIRD, R.N.; MARGARET MEGILL, R.N.; ALEC WITTEK, M.D.; GERALD V. QUINNAN, M.D.; JOSEPH E. PARRILLO, M.D.; ALAIN H. ROOK, M.D.; LAWRENCE J. ERON, M.D.; DONALD M. PORETZ, M.D.; ROBIN I. GOLDENBERG, M.D.; ANTHONY S. FAUCI, M.D.; EDWARD P. GELMANN, M.D.
Eight immunosuppressed homosexual men with cytomegalovirus viremia—seven with serious bilateral retinitis, one with colitis in addition to retinitis, and one with pneumonitis only—were treated with a new acyclovir derivative, 9-(1,3-dihydroxy-2-propoxymethyl) guanine, which has excellent in-vitro activity against cytomegalovirus. All patients had virologic and clinical improvement, but substantial leukopenia developed in three patients. Both clinical relapses and viral relapses occurred frequently, usually within 30 days after cessation of treatment. 9-(1,3-Dihydroxy-2-propoxymethyl) guanine represents the first clinically and virologically effective agent for the treatment of cytomegalovirus disease, but more effective and less toxic therapeutic regimens for both acute and chronic use must be developed.
MASUR H, LANE HC, PALESTINE A, et al. Effect of 9-(1,3-Dihydroxy-2-Propoxymethyl) Guanine on Serious Cytomegalovirus Disease in Eight Immunosuppressed Homosexual Men. Ann Intern Med. 1986;104:41–44. doi: 10.7326/0003-4819-104-1-41
Download citation file:
Published: Ann Intern Med. 1986;104(1):41-44.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use